Clinical Trial Update: Study of Cetuximab and Bevacizumab in Cancer of the Esophagus After Failure of Patient's First Therapy [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating cetuximab in combination with bevacizumab for esophageal carcinoma after failure of first-line therapy has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Carcinoma

Drugs mentioned

• Bevacizumab (bevacizumab)
• Cetuximab (cetuximab)

Snippet

Sponsor: Emory University | Conditions: Esophageal Carcinoma | Phase 2 | Status: WITHDRAWN